進行性非扁平上皮非小細胞肺癌（NSCLC）患者を対象とした、ベバシズマブと標準治療の併用に関する研究

基本情報

NCT ID

NCT01351415

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

485

治験依頼者名

Hoffmann-La Roche

概要

This open-label, randomized, multicenter study will evaluate the efficacy and safety of bevacizumab (Avastin) in combination with standard of care (SOC) treatment in participants with advanced non-squamous NSCLC. Participants will be enrolled at documentation of progression of disease (PD) after 4-6 cycles of first-line treatment with bevacizumab plus a platinum doublet-containing therapy and a minimum of two cycles of bevacizumab maintenance treatment prior to PD. Participants will be randomly assigned to one of two treatment arms to receive either bevacizumab plus SOC treatment or SOC treatment alone.

対象疾患

介入

依頼者（Sponsor）

実施施設 (12)